Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Oncolytics Biotech in a report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.39) per share for the year, up from their prior estimate of ($0.40). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech's FY2027 earnings at ($0.12) EPS.
Separately, Raymond James upgraded shares of Oncolytics Biotech to a "moderate buy" rating in a report on Thursday, November 14th.
View Our Latest Research Report on Oncolytics Biotech
Oncolytics Biotech Stock Performance
TSE:ONC remained flat at C$0.91 during midday trading on Thursday. 28,900 shares of the company were exchanged, compared to its average volume of 123,307. The business has a 50 day moving average of C$1.09 and a two-hundred day moving average of C$1.30. Oncolytics Biotech has a 52 week low of C$0.86 and a 52 week high of C$2.08. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The firm has a market capitalization of C$70.14 million, a PE ratio of -2.54 and a beta of 1.35.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
